novo nordisk obesity drug - Search News

Novo Nordisk Shares Fall

Barron's on MSN · 52m

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on the Way.

Roche agreed to develop a weight-loss drug with Danish biotech Zealand Pharma, pressuring Novo Nordisk and Eli Lilly.

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal · 1d

Novo Nordisk Stock Slides After Obesity Drug Trial Disappoints

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in rival Eli Lilly also sold off. Find out more:

11h

Roche, Zealand Pharma in $5.3 Billion Pact for Obesity Drugs

Roche Holding AG licensed a new weight-loss drug from Zealand Pharma A/S for as much as $5.3 billion, bolstering the Swiss ...

Pharmaceutical Technology23h

Viking strikes $150m deal to secure supply of obesity drug

Viking Therapeutics has inked a $150m multi-year manufacturing deal with CordenPharma to secure the future supply of its ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results